[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371303-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371303-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","patient-derived-organoids-for-guiding-neoadjuvant-chemotherapy-in-bilateral-primary-breast-cancer-a-case-report","Patient-Derived Organoids for Guiding Neoadjuvant Chemotherapy in Bilateral Primary Breast Cancer - A Case Report","","Neoadjuvant chemotherapy (NAC) is standard for locally advanced breast cancer, yet response remains unpredictable because tumor drug sensitivity data are limited. Patient-derived organoids (PDOs) enable drug-sensitivity assessment across cancers. A 46-year-old woman presented with a left-breast mass; core-needle biopsy and pathology confirmed invasive cancer in both breasts, classified as left IIB with axillary metastasis and right IIA. After NAC with albumin-bound paclitaxel, epirubicin, and cyclophosphamide, overall response was partial, but the left tumor was not reduced, so bilateral organoids were cultured.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/patient-derived-organoids-for-guiding-neoadjuvant-chemotherapy-in-bilateral-primary-breast-cancer-a-case-report/371303/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/patient-derived-organoids-for-guiding-neoadjuvant-chemotherapy-in-bilateral-primary-breast-cancer-a-case-report/371303.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why were patient-derived organoids (PDOs) used in this case?","Question",{"text":63,"@type":64},"PDOs were used to assess patient-specific tumor drug sensitivity, because NAC response is unpredictable when information about tumor sensitivity is unknown.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What were the initial treatment and outcomes before organoid-guided therapy?",{"text":68,"@type":64},"The patient received NAC with albumin-bound paclitaxel, epirubicin, and cyclophosphamide. Overall partial response was seen, but the left tumor did not decrease significantly.",{"name":70,"@type":61,"acceptedAnswer":71},"How did organoid testing influence subsequent treatment decisions?",{"text":72,"@type":64},"Organoids cultured from both breasts were tested with PDO-sensitive vinorelbine and carboplatin, leading to partial response in the left tumor compared with the initial state.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371303,1790677292,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","OncoTargets and Therapy  \nOpen Access Full Text Article C ASE REPORT  \nPatient-Derived Organoids for Guiding Neoadjuvant Chemotherapy in Bilateral Primary Breast Cancer: A Case Report  \nMeng Cao 1 , *, Rong Wang2 , *, Xiaohan Cheng 1 , Huiping Yu 3 , Qi Tong4 , Yongzhong Yao 1  \n1Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People’s Republic of China; 2Department of Medical Oncology, Jiangsu Province Hospital, The First Affiliated Hospital With Nanjing Medical University, Nanjing, 210029, People’s Republic of China; 3Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People’s Republic of China; 4Department of Radiology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Yongzhong Yao, Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, People’s Republic of China, Email [njglyyz0124@126.com](njglyyz0124@126.com)  \n\n| Abstract: Neoadjuvant chemotherapy (NAC) is the standard of care for locally advanced breast cancer, but the response to chemotherapy is unpredictable due to unknown information on the tumor drug sensitivity. Patient-derived organoids (PDOs) have recently been revealed to be a promising platform for assessing drug sensitivity in many cancers. A 46-year-old woman presented to the hospital due to an accidentally discovered mass in the left breast. Based on core-needle biopsies, pathologic examination showed invasive breast cancer in both breasts. In combination with immunohistochemistry, the patient was diagnosed with left breast cancer IIB with axillary lymphatic metastasis and right breast cancer IIA. The NAC with albumin-bound paclitaxel, epirubicin and cyclophosphamide was used. Although partial response was assessed overall, the left tumor did not lessen significantly; thus, organoids from bilateral breasts were cultured. After treatment with PDO-sensitive vinorelbine and carboplatin, partial response was achieved in the left compared with the initial tumor. Meanwhile, bilateral mastectomy was performed successfully, with pathological complete response achieved in the right. This typical case suggests that the PDOs from bilateral primary breast cancers can serve as a powerful tool to identify the sensitivity to NAC, thus providing novel treatment options atthe patient-specific level.\u003Cbr>Keywords: bilateral breast cancer, neoadjuvant chemotherapy, organoids, drug sensitivity testing, clinical response |\n| --- |\n| Introduction\u003Cbr>Breast cancer is the most common malignancy in women worldwide and has surpassed lung cancer as the most frequently diagnosed cancer. According to GLOBOCAN estimates, there were approximately 2.31 million new cases of female breast cancer and 0.67 million new deaths in 2022.1 Although over 90% of breast cancer patients are diagnosed at an early stage, there are still a subset of them eventually experiencing recurrence due to the heterogeneous features of breast cancer.2 Currently, the major treatment modalities for breast cancer include surgery, chemotherapy, radiotherapy, and hormonal therapy. Since the 1980s, neoadjuvant chemotherapy (NAC) has been the standard of care for locally advanced breast cancer, which not only makes breast-conserving surgery more feasible but also tends to eliminate micrometastatic lesions.3,4 Nevertheless, it is unpredictable for the response to chemotherapy due to unknown information on the tumor drug sensitivity following treatment initiation.5 Although a lot of patients are treated, only a few of them derive benefits.\u003Cbr>Recently, patient-derived organoids (PDOs), three-d","cbCaiuqjP3Yo4B4E","https://ap.wps.com/l/cbCaiuqjP3Yo4B4E","pdf",4560520,"English","# Abstract\n# Introduction\n# Case Presentation\n# Received / Accepted / Published","[{\"question\":\"Why were patient-derived organoids (PDOs) used in this case?\",\"answer\":\"PDOs were used to assess patient-specific tumor drug sensitivity, because NAC response is unpredictable when information about tumor sensitivity is unknown.\"},{\"question\":\"What were the initial treatment and outcomes before organoid-guided therapy?\",\"answer\":\"The patient received NAC with albumin-bound paclitaxel, epirubicin, and cyclophosphamide. Overall partial response was seen, but the left tumor did not decrease significantly.\"},{\"question\":\"How did organoid testing influence subsequent treatment decisions?\",\"answer\":\"Organoids cultured from both breasts were tested with PDO-sensitive vinorelbine and carboplatin, leading to partial response in the left tumor compared with the initial state.\"}]","Patient-Derived Organoids for Guiding Neoadjuvant Chemotherapy in Bilateral Primary Breast Cancer - A Case Report | PDF",1790191752,15,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a23776d6223d775d694a7f55021bbfda.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/daf77375010f5b1335d3eb9ab480b88d.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58e5c40eda4d3dc3dd0db0962fb679c5.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c952216abf47c4a4b7a6af97988a86aa.webp",980,1268]